Trading Summary - February 27. Another satisfactory

New Post Public Reply Private Reply Replies (0) Message Board
AJH92
132
Trading Summary - February 27.

Another satisfactory status quo day for $DIGX whilst we await the anticipated record Q4 results.

The fake 10M ask block put up yesterday - which was thought to be from one of the basher / flippers still trying to get .0003s before the Q4 - was cancelled before the open along with another 2M.

3 ludicrous paint downs were made for 250K, 5000 and 4999 shares - with no effect of course.

The bid at .0003 was maintained at a more than adequate level - 71M > 80M - to keep the basher / flippers boxed out from getting any more .0003s.

Another day closer to the PR announcing the provisional 2017 revenue and profits - expected to be a record again - and hopefully also outlining acquisition / growth plans for 2018. In 2017, this PR came out on Feb 28.

Also, before the end of the week we should get another update to the Verified Company Profile confirming no dilution in 2017 and to date in 2018.

As always, anything could happen at anytime. So stay sharp if you don't already have all the shares you need to make your profit expectations up to Q4 in March 2018 and thereafter throughout 2018.

Prior warning and / or scanner alerts of any significant buys starting a run up will not be given on iHub but they will be alerted here immediately.

Content below the line unchanged from the last update - relevant to those that are new here.

The following items have not been PR'ed yet:

- Shares retired in 2017 (425M known to followers here but not PR'ed yet).

- Excellent 3Q results.

- Provisional 4Q results - including anticipated dramatic increase over 3Q due to additional services now being provided in the chiropractic offices - in Strategic Growth Plan - equipment already acquired at start of Q4).

- Further acquisition plans for brand growth.

In due course, the Q4 results will speak for themselves and - when PR'ed to the wider investing community - we should see serious additional new interest due to the low O/S and relatively high positive revenue for a stock in this price range - just as happened for the 2016 Q4 and the 2017 Q1 and Q2.

The long-term whales who trade $DIGX will continue to buy shares at any price that makes sense to them to use on multiple runs throughout 2018. It is already known from posted comments and observation that at least 4 of the main whales bought shares - on the bid and on the ask - from the impatient at the end of 2017.

As predicted, at least 4 x whales who trade $DIGX continuously throughout each year were happy to take around 100M at .0003 when a few impatient people decided to trade for a loss at .0003 on December 14.

As predicted in October 2017, $DIGX was not allowed to go to the 2016 year-end low of .0002 ask at end-2017.

As predicted, the .0004s were bought out in just 2 individual seconds and the same is likely to happen with the .0005s.at some point - setting off a run towards .0010 - just like happened in 2017 before the first PR.

Any shares bought at .0004 should be worth an easy 150%+ profit on any of numerous runs likely to happen through to Q4. Shares bought at .0005 should easily return 100%+ at some point in 2018.

The big boys in DIGX now probably already have an inventory of 50M>200M each for trading throughout 2018.

Ludicrous claims by the notorious bashers on iHub - "RFB", "munimi", "surfkast:, "Crown Capital" and "Homebrew" - are clearly seen as such by all serious traders and now even by most iHubbers.

Money is not considered "dead" by the most successful traders in the OTC market when they know it will provide a significant return further down the line because they are in a position to understand and influence - through keen observation and record keeping - what volume of shares is likely to be made available for purchase at any particular level.










American EcoFuels Inc (AEFI) Stock Research Links

AEFI Board Company Profile Buy Rating Time & Sales News Filings Financials
"Per Ardua Ad Astra" - "Through Adversity To The Stars"

A very apposite motto for those who trade successfully in the OTC market..

All posts are my opinion - trade at your own risk.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

LG's ASIL D Certification: A Game Changer in Autos

Updated Category News Views 170

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 108

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 358

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 336

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 364

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 153

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 86

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 372

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Cultural Tech Fusion: The Asia-Pacific Way Forward

Updated Category News Views 64

A High-Tech Twist on Traditional Culture You ever walk into a room and see a robot perform kung fu? I'll admit, it caught me off guard at first. But that's exactly what happened at the "Enduring Heritage, Harmonious Asia-Pacific" special exhibition in Shenzhen. With all the usual high-ranking execs and cultural bigwigs there, nobody expected a showcase where Wing Chun...

Continue Reading

Top 5 Most Recently Viewed Articles

Analyzing Trump's Executive Orders and Their Economic Impact

Updated Category News Views 806

Executive Orders: A Shift in Economic Paradigms President Trump has taken significant steps by issuing a number of executive orders that have raised eyebrows among economists and market analysts alike. According to market expert Louis Navellier, this approach can be characterized as 'shock and awe'. It reflects a bold strategy that could reshape various aspects of the...

Continue Reading
B2PRIME Expands Institutional Reach with Stuart Brock's Addition

Updated Category News Views 173

B2PRIME Welcomes Stuart Brock as Institutional Business Development Manager B2PRIME Group, a leading financial services provider for institutional and professional clients, recently announced the appointment of Stuart Brock as its Institutional Business Development Manager. With over 15 years of experience in electronic trading and institutional sales, Stuart is poised to...

Continue Reading
United Parks & Resorts Inc. Shares Q1 2025 Financial Insights

Updated Category News Views 374

Financial Overview of United Parks & Resorts Inc. United Parks & Resorts Inc. (NYSE: PRKS), a prominent player in the theme park and entertainment sector, has recently shared its financial results for the first quarter of 2025. This report delves into the key metrics and operational insights that define the company’s performance in this period. Attendance and Revenue...

Continue Reading
Seongnam Pavilion Sets New Benchmark at CES 2025 with 41 Companies

Updated Category News Views 178

Seongnam Pavilion Makes Waves at CES 2025 At the latest CES 2025, Seongnam City showcased an impressive turnout at the world's leading consumer electronics exhibition. This year, Seongnam participated with a remarkable delegation of 41 companies, marking the largest participation ever. Focused on enhancing their global footprint, these small and medium-sized enterprises...

Continue Reading
Gaucho Holdings Seizes Opportunities Amid Argentina's Economic Revival

Updated Category News Views 179

Gaucho Holdings and the New Economic Landscape in Argentina Recently, Argentina has entered a new chapter of economic transformation. A shift in leadership, with Javier Milei becoming president, has sparked hopes for fiscal discipline, growth, and development. As the country embraces pro-market reforms, Gaucho Group Holdings, Inc. (NASDAQ: VINO) positions itself to...

Continue Reading